Top 5 Drug Type | Count |
---|---|
Small molecule drug | 3 |
AAV based gene therapy | 3 |
Diagnostic radiopharmaceuticals | 2 |
Recombinant protein | 1 |
Synthetic peptide | 1 |
Target |
Mechanism TGF-β1 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism Gene transference |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Oct 2025 |
Sponsor / Collaborator |
Start Date01 Mar 2025 |
Sponsor / Collaborator |
Start Date10 Jan 2025 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Disitertide ( TGF-β1 ) | Scleroderma, Systemic More | Phase 2 |
CM-272 ( DNMT1 x EHMT2 ) | Hematologic Neoplasms More | Preclinical |
AS-10 | Colorectal Cancer More | Preclinical |
89Zr-anti-PD-1 ( PD-1 ) | Lung Cancer More | Preclinical |
AAV8-AAT-ATP7B ( ATP7B ) | Hepatolenticular Degeneration More | Preclinical |